Company Focus
Sun Pharmaceuticals
Latest Sun Pharmaceuticals News
Pharmaceutical
As the US government, under President Donald Trump, is on the verge of announcing significant new tariffs on pharmaceutical imports, Indian drug-maker stocks continue to take a hammering on the bourses. 8 May 2025
Related News
Insights
Company Spotlight
A Germany-based biotech aiming to grow into a major global biopharmaceutical player by following a company buy-and-build approach.
Latest News & Features of interest to Sun Pharmaceuticals
Pharmaceutical
French biotech Ciloa is joining the race to treat type 2 diabetes and obesity, armed with 6.5 million euros ($7.6 million) in public funding and a novel take on an old metabolic target. 9 July 2025
Pharmaceutical
A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in atopic dermatitis (AD), pointing to a rising risk of failure driven by flawed trial design and overreliance on saturated investigator sites. 9 July 2025
Biotechnology
San Francisco, USA-based biotech Centivax, which is developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors. 8 July 2025
Pharmaceutical
Switzerland-based MetP Pharma, pioneer in nose-to-brain drug delivery for nearly two decades, announced new data highlighting the advantages of its proprietary MetP Technology in delivering neuroactive peptides such as semaglutide directly to the brain via the intranasal route. 8 July 2025
Biotechnology
Shares of US clinical-stage biotech Apogee Therapeutic closed down 17.3% at $39.24 yesterday, despite announcing positive 16-week data from Part A of the Phase II APEX clinical trial of APG777, a potential best-in-class anti-interleukin (IL)-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD). 8 July 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceutical has entered into a joint research and license agreement to develop novel therapies for age-related diseases with Singapore-based biotech Gero. 7 July 2025
Biotechnology
Actinogen Medical (ASX: ACW), an Australian biotech, announced that the 100th participant in its pivotal XanaMIA Phase IIb/III randomized trial of Xanamem (emestedastat) for Alzheimer's disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. 7 July 2025
Pharmaceutical
A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections. 7 July 2025
Biotechnology
Austria’s HeartBeat.bio and biotx.ai have announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. 7 July 2025
Biotechnology
US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate CPTX2309, for up to $2.1 billion. Organon posted disappointing mid-stage trial results for its investigational endometriosis pain drug, OG-6219. Also of note last week, the US Food and drug Administration (FDA) granted accelerated approval for Regeneron’s multiple myeloma drug Lynozyfic. 6 July 2025
Latest In Brief for Sun Pharmaceuticals
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Relevant Ones To Watch News
US pharma major AbbVie announced it plan to acquire Capstan Therapeutics, along with its autoimmune disease candidate CPTX2309, for up to $2.1 billion. Organon posted disappointing mid-stage trial results for its investigational endometriosis pain drug, OG-6219. Also of note last week, the US Food and drug Administration (FDA) granted accelerated approval for Regeneron’s multiple myeloma drug Lynozyfic. 6 July 2025
17 June 2025
16 June 2025
12 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze